Targeting CD133 high colorectal cancer cells in vitro and in vivo with an asymmetric bispecific antibody

Journal of Immunotherapy

Volumn 38, Issue 6, 2015, Pages 217-228

  Zhao, Lei ^a   Yang, Yudan ^a   Zhou, Pengfei ^b   Ma, Hong ^a   Zhao, Xiaolai ^a   He, Xin ^a   Wang, Tao ^b   Zhang, Jing ^b   Liu, Yang ^b   Zhang, Tao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b YZY Biopharma Co Ltd   (China)

Author keywords

bispecific antibody; cancer stem cells; CD133; colorectal neoplasm; immunotherapy

Indexed keywords

BISPECIFIC ANTIBODY; CD133 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHIMERIC ANTIBODY; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOMER; OKT 3; TUMOR ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; PEPTIDE;

ADULT; ADVANCED CANCER; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHATIC SYSTEM; MOUSE; NOD SCID MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR INVASION; ANIMAL; COLORECTAL NEOPLASMS; CYTOTOXICITY; GENETIC ENGINEERING; GENETICS; HCT116 CELL LINE; HEK293 CELL LINE; HT 29 CELL LINE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; SCID MOUSE; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD3; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; GENETIC ENGINEERING; GLYCOPROTEINS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HCT116 CELLS; HEK293 CELLS; HT29 CELLS; HUMANS; IMMUNOTHERAPY; IN VITRO TECHNIQUES; INTERFERON-GAMMA; MICE, SCID; MOLECULAR TARGETED THERAPY; PEPTIDES; T-LYMPHOCYTES;

EID: 84933527123     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000086     Document Type: Article

References (41)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.
2. Zheng ZX, Zheng RS, Zhang SW, et al. Colorectal cancer incidence and mortality in China, 2010. Asian Pac J Cancer Prev. 2014;15:8455-8460.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
4. Hazama S, Nakamura Y, Tanaka H, et al. A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med. 2014;12:108-117.
5. Patel P, Chen EI. Cancer stem cells, tumor dormancy, and metastasis. Front Endocrinol (Lausanne). 2012;3:125-129.
6. + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27:1749-1758.
7. + sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys. 2007;67:1-5.
8. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2006;445:106-110.
9. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2006;445:111-115.
10. Horst D, Kriegl L, Engel J, et al. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008;99:1285-1289.
11. Smith LM, Nesterova A, Ryan MC, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 2008;99:100-109.
12. Yao J, Zhang T, Ren JH, et al. Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells. Oncol Rep. 2009;22:781-787.
13. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69:4941-4944.
14. Goere D, Flament C, Rusakiewicz S, et al. Potent immunomodulatory effects of the trifunctional antibody catumaxo-mab. Cancer Res. 2013;73:4663-4673.
15. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974-977.
16. Moore PA, Zhang W, Rainey GJ, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood. 2011;117:4542-4551.
17. Zhang P, Shi B, Gao H, et al. An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression. Cancer Immunol Immun-other. 2014;63:121-132.
18. Ruf P, Kluge M, Jager M, et al. Pharmacokinetics, immuno-genicity and bioactivity of the therapeutic antibody catumax-omab intraperitoneally administered to cancer patients. Br J Clin Pharmacol. 2010;69:617-625.
19. Takahashi S, Kamiyama T, Tomaru U, et al. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep. 2010;24:1201-1212.
20. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmaco-logic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012; 119:6226-6233.
21. Horst D, Scheel SK, Liebmann S, et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol. 2009;219:427-434.
22. Huang J, Li C, Wang Y, et al. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol. 2013;149:156-168.
23. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimeriza-tion. Protein Eng. 1996;9:617-621.
24. Xie Z, Guo N, Yu M, et al. A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods. 2005;296:95-101.
25. Junttila TT, Li J, Johnston J, et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res. 2014;74:5561-5571.
26. Gunasekaran K, Pentony M, Shen M, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem. 2010;285:19637-19646.
27. Schaefer W, Regula JT, Bahner M, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA. 2011;108: 11187-11192.
28. Zeidler R, Mysliwietz J, Csanady M, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000;83:261-266.
29. Lamers CH, van de Griend RJ, Braakman E, et al. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int J Cancer. 1992;51:973-979.
30. Yano H, Thakur A, Tomaszewski EN, et al. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. J Transl Med. 2014;12:191-201.
31. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.
32. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65: 10946-10951.
33. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007; 1:313-323.
34. Csermely P, Hodsagi J, Korcsmaros T, et al. Cancer stem cells display extremely large evolvability: alternating plastic and rigid networks as a potential Mechanism: network models, novel therapeutic target strategies, and the contributions of hypoxia, inflammation and cellular senescence. Semin Cancer Biol. 2015;30:42-51.
35. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756-760.
36. + cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67-78.
37. Arndt K, Grinenko T, Mende N, et al. CD133 is a modifier of hematopoietic progenitor frequencies but is dispensable for the maintenance of mouse hematopoietic stem cells. Proc Natl Acad Sci USA. 2013;110:5582-5587.
38. Adini A, Adini I, Ghosh K, et al. The stem cell marker prominin-1/CD133 interacts with vascular endothelial growth factor and potentiates its action. Angiogenesis. 2013;16: 405-416.
39. Florek M, Haase M, Marzesco AM, et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 2005;319:15-26.
40. Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther. 2004;3:1493-1501.
41. Christiansen JJ, Rajasekaran SA, Inge L, et al. N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immuno-therapy. Mol Cancer Ther. 2005;4:704-714.